Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Mochida Pharmaceutical Co., Ltd. currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units. This distribution indicates a diverse prosecution landscape where each matter is being handled independently in a different specialized group.
The busiest examiner for this portfolio is GROUX, JENNIFER LILA, who is managing 1 busiest examiner pending action. This workload represents 1 of the 3 pending office actions currently facing the company. Since there are 3 distinct examiners, no single official is responsible for more than 1 of the pending matters, ensuring a variety of perspectives during examination.
The involvement of the identified art units suggests that the company's biotechnology and pharmaceutical applications cover a range of specific sub-disciplines. With the workload spread across multiple examiners, the prosecution may lead to varying timelines and outcomes depending on the specific practices of each of the 3 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GROUX, JENNIFER LILA | 1 | 34.8% | +39.3% |
| LANKFORD JR, LEON B | 1 | 70.0% | +31.6% |
| TINSLEY, BRENDAN THOMAS | 1 | 58.7% | +73.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557890 | PRESEPSIN MARKER PANELS FOR EARLY DETECTION OF SEPSIS | LANKFORD JR, LEON B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273654 | COMPOSITION FOR REGENERATION OF INTERVERTEBRAL DISC | TINSLEY, BRENDAN THOMAS | 62d |
| 18876878 | GEL FIBER MANUFACTURING APPARATUS AND MANUFACTURING METHOD | GROUX, JENNIFER LILA | — |
| 18557890 | PRESEPSIN MARKER PANELS FOR EARLY DETECTION OF SEPSIS | LANKFORD JR, LEON B | — |
| Art Unit | Apps |
|---|---|
| 1754 | 1 |
| 1657 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18876878 | GEL FIBER MANUFACTURING APPARATUS AND MANUFACTURING METHOD | GROUX, JENNIFER LILA | 1754 | §102 | Non-Final OA | — | Pending | Dec 19, 2024 |
| 18557890 | PRESEPSIN MARKER PANELS FOR EARLY DETECTION OF SEPSIS | LANKFORD JR, LEON B | 1657 | §102§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18273654 | COMPOSITION FOR REGENERATION OF INTERVERTEBRAL DISC | TINSLEY, BRENDAN THOMAS | 1634 | DP | Final Rejection | 62d | Pending | Jul 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial